Single exposure of dopamine D1 antagonist prevents and D2 antagonist attenuates methylphenidate effect

Catherine M Claussen1, Lindsey J Witte1, Nachum Dafny1

  • 1Department of Neurobiology and Anatomy, The University of Texas Health Science Center Medical School at Houston, Houston, TX, USA.

Insights

Methylphenidate (MPD) causes increased locomotor activity in rats, a process known as behavioral sensitization. Dopamine D1 receptors play a significant role in this MPD-induced sensitization, while D2 receptors have a minor modulatory effect.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Behavioral Science

Background:

  • Methylphenidate (MPD) is prescribed for ADHD and misused for cognitive enhancement.
  • MPD exposure in rodents increases locomotor activity, with repetitive use leading to behavioral sensitization.
  • Dopamine (DA) is implicated in MPD's acute and chronic effects, but its precise role via specific receptors is debated.

Purpose of the Study:

  • To investigate the involvement of D1 and D2 dopamine receptors in the acute and chronic effects of MPD on locomotor activity.

Main Methods:

  • Seven groups of male Sprague Dawley rats were used over 12 days.
  • A single D1 or D2 antagonist was administered before and after acute and chronic MPD exposure.
  • Locomotor activity was measured as a behavioral marker.

Main Results:

  • D1 antagonist significantly attenuated MPD-induced locomotor activity when given before initial and after repetitive MPD exposure.
  • D2 antagonist partially attenuated locomotor activity only when administered before the second MPD exposure.
  • These findings suggest a partial role for D1 DA receptors in MPD behavioral sensitization.

Conclusions:

  • Dopamine D1 receptors are significantly involved in methylphenidate-induced behavioral sensitization.
  • Dopamine D2 receptors appear to partially modulate the acute and chronic responses to methylphenidate.

Related Concept Videos

Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.5K
Adrenergic Agonists: Indirect-Acting Agents01:25

Adrenergic Agonists: Indirect-Acting Agents

Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
3.0K
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
1.6K
Adrenergic Agonists: Chemistry and Structure-Activity Relationship01:16

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
4.1K
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
1.0K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K